# 默克取得中國藥廠翰森製藥一款實驗性減重藥物的權利。

*biotech · news · 2024-12-18 · CNBC*

## Key points

- 默克取得翰森製藥實驗性口服GLP-1藥物HS-10535的全球獨家權利。
- 該協議價值最高可達20億美元，默克已預付1.12億美元給翰森。
- HS-10535尚未進入人體試驗，默克尚未透露初步測試適應症。
- 默克目標是該藥能提供超越減重的心臟代謝益處。
- 此舉符合西方藥廠授權中國開發的實驗性GLP-1藥物的趨勢。

Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey. Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. The oral drug has not yet entered human trials, and Merck did not specify which diseases it plans to test the drug on first. Still, it boosts the pharmaceutical company's chances of winning a slice of the booming obesity drug market, which some analysts expect to be worth more than $100 billion a year by the early 2030s. Several other drugmakers, including Pfizer and Roche , are racing to develop more convenient obesity pills that can compete with blockbuster injections from Novo Nordisk and Eli Lilly . Under the terms of the deal, Merck will gain the exclusive global license to develop, manufacture and commercialize Hansoh Pharma's HS-10535, an experimental oral drug that targets a gut hormone called GLP-1. Novo Nordisk's popular weight loss drug Wegovy and diabetes treatment Ozempic similarly target GLP-1 to tamp down appetite and regulate blood sugar. Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in milestone payments and royalties on sales, according to a news release. Merck said a pretax charge of $112 million, or 4 cents per share, will be included in its fourth-quarter results. In the release, Dean Li, president of Merck Research Laboratories, said the oral drug has "potential to provide additional cardiometabolic benefits beyond weight reduction." Merck CEO Rob Davis early last year said the company was seeking GLP-1 treatments with benefits beyond weight loss. "I think everyone recognizes weight management is a hard thing to get reimbursed. But if you can show cardiovascular outcome, if you can show diabetes outcome, which you're starting to see data for, if you can see fatty liver disease benefits ... that is an area where we think there's opportunity," he said at a conference at the time. It is the latest transaction involving experimental GLP-1 drugs from China. AstraZeneca last year licensed Chinese company Eccogene's experimental oral drug, which has since moved into mid-stage development.

**Companies:** Merck, Pfizer, Roche
**Countries:** China, United States

[Read the full story on CNBC](https://www.cnbc.com/2024/12/18/merck-weight-loss-pill-licensing-deal-hansoh-pharma.html)

---

Canonical: https://newsio.io/zh-TW/n/731a0e81-4266-4fdf-9475-f5474fd631ce/
Summarized by Newsio from CNBC. https://newsio.io/how-it-works